Ignite Creation Date:
2024-05-05 @ 5:19 PM
Last Modification Date:
2024-10-26 @ 9:30 AM
Study NCT ID:
NCT00434239
Status:
UNKNOWN
Last Update Posted:
2013-01-10
First Post:
2007-02-11
Brief Title:
Lenalidomide and Recombinant Human Stem Cell Factor for Treatment of Myelodysplasia
Sponsor:
Peter MacCallum Cancer Centre Australia
Organization:
Peter MacCallum Cancer Centre Australia
Study Overview
Official Title:
A Pilot Study of the Combination of Lenalidomide Revlimid With Two Different Dose Levels of Short Term Administration of Recombinant Human Stem Cell Factor rhSCF Ancestim for Myelodysplasia
Status:
UNKNOWN
Status Verified Date:
2013-01
Last Known Status:
ACTIVE_NOT_RECRUITING
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This study is mainly assessing the safety of Revlimid in combination with Ancestim recombinant human stem cell factor in patients with symptomatic myelodysplasia Of those two compounds Revlimid has been shown to be an active drug in myelodysplasia Clinical responses will also be assessed
Detailed Description:
Aim The primary objective is to assess the safety of Revlimid in combination with Ancestim in patients with symptomatic myelodysplasia The secondary objectives are Duration of response and assessment of changes in gene expression profile of bone marrow samples from patients undergoing such treatment
Potential Significance Myelodysplastic syndromes MDS are malignant hematopoietic stem cell disorders Prognosis can be estimated by use of the International Prognostic Scoring System IPSS which divides patients into low intermediate-1 intermediate-2 and high-risk groups with corresponding median survival times of 57 years 35 years 12 years and 04 years respectively There is currently no standard treatment for MDS and management is often purely symptomatic with transfusion of blood products and antibiotic treatment of infections
A recent phase II study however has shown significant response rates with Revlimid as a single agent in patients with MDS The total response rate was 56 The effects of Revlimid and SCF on hematopoietic progenitors cells were examined in vitro RhSCF and Revlimid were shown to be synergistic in stimulating the proliferation of hematopoietic progenitor cells and their precursors in vitro thereby forming the rationale for this study
Research Plan This is a single-centre open label single-arm non-comparative study in which 25 patients will be enrolled The study will include patients who meet all the inclusion and none of the exclusion criteria as per the respective protocol section
The patients will be enrolled sequentially to receive 2 different dose levels of Ancestim with a fixed dose of Revlimid This will determine the feasibility and tolerability of the combination of Revlimid and Ancestim Patients will start with an 8 week course of single agent Revlimid as 10mg daily oral treatment day 1-21 in a 28 day cycle If patients do not achieve a complete remission on single agent Revlimid they will start on Ancestim sc injections Two dose levels of Ancestim 10 and 20 mcgkg sc daily for 7 days will be evaluated
Safety Safety will be assessed by the reporting of adverse events starting with the first study-related procedure during treatment and for a period of 60 days following discontinuation of treatment The intensity of the adverse events will be assessed using National Cancer Institute common toxicity criteria All adverse events will be recorded on the case report forms CRFs Furthermore assessments of physical including neurological peripheral neurological examinations vital signs measurements and haematology and clinical chemistry tests will be used to monitor safety Clinically relevant changes in laboratory safety tests vital signs and physical examinations will be recorded as adverse events The adverse event sections of the CRFs will be submitted to a representative of the sponsor at the end of each treatment cycle Serious adverse events will be reported as they occur on forms provided by the sponsor
Efficacy Response to treatment will be assessed according to the guidelines of the international working group to standardize response criteria for myelodysplastic syndromes This will be done on bone marrow biopsies including cytogenetic analyses and peripheral blood counts An additional scientific investigation will examine gene-expression profiles of bone-marrow and blood samples at different time points and will try to correlate those with response to treatment Concomitant in-vitro studies will assess surrogate markers of response
Statistical Methods Adverse events serious adverse events transfusion requirements response data and Karnofsky performance status data will be summarized
Potential Significance Myelodysplastic syndromes MDS are malignant hematopoietic stem cell disorders Prognosis can be estimated by use of the International Prognostic Scoring System IPSS which divides patients into low intermediate-1 intermediate-2 and high-risk groups with corresponding median survival times of 57 years 35 years 12 years and 04 years respectively There is currently no standard treatment for MDS and management is often purely symptomatic with transfusion of blood products and antibiotic treatment of infections
A recent phase II study however has shown significant response rates with Revlimid as a single agent in patients with MDS The total response rate was 56 The effects of Revlimid and SCF on hematopoietic progenitors cells were examined in vitro RhSCF and Revlimid were shown to be synergistic in stimulating the proliferation of hematopoietic progenitor cells and their precursors in vitro thereby forming the rationale for this study
Research Plan This is a single-centre open label single-arm non-comparative study in which 25 patients will be enrolled The study will include patients who meet all the inclusion and none of the exclusion criteria as per the respective protocol section
The patients will be enrolled sequentially to receive 2 different dose levels of Ancestim with a fixed dose of Revlimid This will determine the feasibility and tolerability of the combination of Revlimid and Ancestim Patients will start with an 8 week course of single agent Revlimid as 10mg daily oral treatment day 1-21 in a 28 day cycle If patients do not achieve a complete remission on single agent Revlimid they will start on Ancestim sc injections Two dose levels of Ancestim 10 and 20 mcgkg sc daily for 7 days will be evaluated
Safety Safety will be assessed by the reporting of adverse events starting with the first study-related procedure during treatment and for a period of 60 days following discontinuation of treatment The intensity of the adverse events will be assessed using National Cancer Institute common toxicity criteria All adverse events will be recorded on the case report forms CRFs Furthermore assessments of physical including neurological peripheral neurological examinations vital signs measurements and haematology and clinical chemistry tests will be used to monitor safety Clinically relevant changes in laboratory safety tests vital signs and physical examinations will be recorded as adverse events The adverse event sections of the CRFs will be submitted to a representative of the sponsor at the end of each treatment cycle Serious adverse events will be reported as they occur on forms provided by the sponsor
Efficacy Response to treatment will be assessed according to the guidelines of the international working group to standardize response criteria for myelodysplastic syndromes This will be done on bone marrow biopsies including cytogenetic analyses and peripheral blood counts An additional scientific investigation will examine gene-expression profiles of bone-marrow and blood samples at different time points and will try to correlate those with response to treatment Concomitant in-vitro studies will assess surrogate markers of response
Statistical Methods Adverse events serious adverse events transfusion requirements response data and Karnofsky performance status data will be summarized
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None